CepTor Corporation (CEPO.OB) Reports Significant Reduction Of Multiple Sclerosis (MS) Symptoms With Oral Delivery Of Neurodur In EAE Model
10/12/2006 11:34:42 AM
More...
|
CepTor Corporation (CEPO.OB) Reports Two Issues Remain To Move Myodur IND Forward
10/9/2006 12:04:42 PM
More...
|
CepTor Corporation (CEPO.OB) Executes LOI With Ferring For Late Stage Product; Superoxide Dismutase Targeted For Phase 2B Clinical Trials
9/15/2006 9:57:37 AM
More...
|
CepTor Corporation (CEPO.OB) Seeks Approval To Initiate Clinical Trial Of Myodur For Muscular Dystrophy; Submits IND Complete Response To FDA
9/12/2006 10:08:43 AM
More...
|
CepTor Corporation (CEPO.OB) Retains Oppenheimer & Co. To Enhance Shareholder Value
5/3/2006 1:06:14 PM
More...
|
CepTor Corporation (CEPO.OB) Presents Statistically Significant Proof Of Concept Data On Myodur For Muscular Dystrophy At The American Academy Of NeurologyMeeting
4/25/2006 1:18:36 PM
More...
|
CepTor Corporation (CEPO.OB) Adopts Shareholder Rights Plan
3/9/2006 11:01:07 AM
More...
|
CepTor Corporation (CEPO.OB) Retains Banyan Biomarkers To Develop Test To Evaluate Effectiveness Of Myodur For Muscular Dystrophy
2/7/2006 1:29:28 PM
More...
|
CepTor Corporation (CEPO.OB) Receives Dual Orphan Drug Designation For Myodur (C101) For Duchenne And Becker Muscular Dystrophies
1/25/2006 1:14:19 PM
More...
|
CepTor Corporation (CEPO.OB) Submits Investigational New Drug Application (IND) To Initiate Clinical Trials With Myodur (C-101) In Duchenne Muscular Dystrophy (DMD) Patients
1/17/2006 12:03:16 PM
More...
|
|